Recombinant Human PCDH12 protein

**Background of PCDH12 Recombinant Protein**

Protocadherin-12 (PCDH12), a member of the cadherin superfamily, is a calcium-dependent cell adhesion protein primarily involved in cell-cell interactions and tissue morphogenesis. It belongs to the non-clustered δ2-protocadherin subgroup, characterized by extracellular cadherin repeats and a cytoplasmic domain lacking conserved signaling motifs. PCDH12 is expressed in endothelial cells, the placenta, and the developing nervous system, where it plays critical roles in vascular development, blood-brain barrier formation, and placental angiogenesis.

Studies highlight its importance in embryogenesis, particularly in vascular and neural network assembly. PCDH12 interacts with vascular endothelial growth factor (VEGF) signaling pathways, influencing endothelial cell migration and tube formation. Dysregulation of PCDH12 has been linked to pathological conditions, including preeclampsia, intrauterine growth restriction, and cancer metastasis, underscoring its role in maintaining vascular integrity and tissue homeostasis.

Recombinant PCDH12 protein is engineered to study its structural and functional properties in vitro. Produced using expression systems like mammalian cells (e.g., HEK293) or bacteria, the recombinant protein retains key domains for ligand binding and cellular adhesion. It is purified via affinity tags (e.g., His-tag) and validated for bioactivity through cell adhesion or migration assays.

Research applications include investigating PCDH12’s role in endothelial barrier function, tumor angiogenesis, and placental development. It also serves as a tool for generating antibodies or screening therapeutic agents targeting vascular or neurological disorders. By elucidating PCDH12’s molecular interactions, researchers aim to develop strategies for treating diseases linked to vascular dysfunction or abnormal cell adhesion.